The graph you posted is the combined US and Australian data. If we accept that the US concentrations were botched at manufacture then I think it quite reasonable to imply that a twice daily application in the US could have reduced efficacy. It's the Australian data that has more weight IMO as it aligns more closely with phase I results.
What's the vehicle anyhow?, page-54
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $640.6M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 34.5¢ | $1.196M | 3.408M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 522054 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 434961 | 11 |
View Market Depth
| Last trade - 13.33pm 17/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |